Your browser version may not work well with NCBI's Web applications. More information here...
1: Neurology. 2006 Nov 14;67(9 Suppl 3):S2-5.Click here to read Links

Primary prevention trials in Alzheimer disease.

Green RC, DeKosky ST.

Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA. rcgreen@bu.edu

Many new treatments under development for Alzheimer disease (AD) will be disease-modifying rather than symptomatic. Clinical evaluation of these treatments will require primary and secondary prevention trials. We describe some of the methodologic challenges in designing primary prevention trials for AD and illustrate these with examples from the ADAPT (Alzheimer Disease Anti-Inflammatory Prevention Trial) Study and GEM (Ginkgo in Evaluation of Memory) Study. Primary prevention trials for AD present many design challenges. In most situations, secondary prevention trials provide the most feasible first step toward primary prevention.

PMID: 17101930 [PubMed - indexed for MEDLINE]